New study reveals certain bacteria are toxic for head and neck cancer
Head and neck cancer is currently recognised as the sixth most common cancer globally
Read More
Tag: head and neck cancer
FluoGuide announces head and neck cancer therapy results
The treatment is administered intravenously prior to surgery, lighting up cancer during surgery
Read More
NICE backs Opdivo for head and neck cancer
New evidence collected through the CDF shapes recommendation
Read More
GSK decides to halt mid-stage feladilimab studies
British drugmaker has discontinued treatment with investigational drug in two cancer trials
Read More
AZ’s Imfinzi fails to improve overall survival in head and neck cancer again
Immunotherapy has previously failed in this therapy area
Read More
NICE no for BMS’ Opdivo for head and neck cancer
Opdivo is currently available on the Cancer Drugs Fund
Read More
US expands scope of MSD’s Gardasil
The indication is approved under accelerated approval
Read More
AZ’ Imfinzi fails in head and neck cancer trial
AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Read More
Immunotherapy extends the life of head and neck cancer patients
A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, reports a major new clinical trial.
Read More
UK trial assessing AZ’ AZD1775 in head and neck cancer
A clinical trial testing AstraZeneca’s experimental drug AZD1775, an inhibitor of the cell cycle regulating protein WEE1, in patients with head and neck cancer has now launched in the UK.
Read More
New deal secures Opdivo an NHS spot for head and neck cancer
Bristol-Myers Squibb’s Opdivo will be available on the NHS for squamous cell carcinoma of the head and neck after all, following a u-turn by the National Institute for Health and Care Excellence.
Read More
Merck’s Erbitux backed by NICE for head and neck cancer
Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell cancer of the head and neck.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
